Emerging Infectious Disease ISSN: 1080-6059
Volume 17, Number 1—January 2011
Dispatch
Serodiagnosis of Primary Infections with Human Parvovirus 4, Finland
Figure 1

Figure 1. Parvovirus 4 (PARV4) virus-like particle (VLP) expression and immunoreactivity, Finland. A) Sodium dodecyl sulfate–polyacrylamide gel electrophoresis of PARV4-like particles in Spodoptera frugiperda armyworm (Sf)9 cells (lane 1), purified VLPs (lane 2), and uninfected Sf9 cells (lane 3). B) Western blotting with PARV4 immunoglobulin (Ig) G–positive serum (lanes 1, 3, and 4) or PARV4 IgG–negative serum (lane 2). Lanes 1 and 2, purified VLPs as antigen; lane 3, Sf9 cells expressing VLPs; lane 4, Sf9 cells expressing glutathione-S-transferase control antigen; lanes M, molecular mass marker. Arrows in panels A and B indicate the PARV4 capsid protein. C) Electron micrograph of purified VLPs. Scale bar = 200 nm.
Lessons from the History of Quarantine, from Plague to Influenza A
Length: 23:11





